London, 27 November, 2019 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational pharmaceutical company, today announces that it has submitted to the US Food and Drug Administration (FDA) its response to deficiencies in its abbreviated new drug application (ANDA) for a generic version of GlaxoSmithKline’s Advair Diskus® (fluticasone propionate and salmeterol inhalation powder).
27 November 2019
Following receipt of a complete response letter (CRL) from the FDA, Hikma initiated a clinical endpoint study in 2018. This study has been completed and it, along with other information requested by the FDA, has been submitted to the FDA for review. The submission addresses the outstanding questions raised by the FDA in its CRL.
Siggi Olafsson, Chief Executive Officer of Hikma, said “Our team has worked extremely hard with Vectura to complete a large and challenging clinical study, which we believe demonstrates the safety and effectiveness of our product, and I am very pleased to have responded to the FDA. As we continue to develop our pipeline of complex generics, respiratory products are a key strategic focus for Hikma and our generic Advair submission is an important milestone. We are confident in our ability to bring a generic version of Advair to the US market, which would enable us to improve patient access to this important medicine.”